CAROLYN BECKER: Open Payments
NPI 1255479176 · DENVER, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,132 in 43 payments from 25 companies in 2025. Trend: 2023 $5,970 · 2024 $2,264 · 2025 $1,132
Food & beverage: $1,032Education: $100
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 6 | $200 |
| Genmab U.S., Inc. | 2 | $139 |
| ABBVIE INC. | 4 | $81 |
| Eisai Inc. | 3 | $76 |
| PFIZER INC. | 3 | $53 |
| ADC THERAPEUTICS AMERICA, INC. | 3 | $52 |
| Incyte Corporation | 2 | $51 |
| Novartis Pharmaceuticals Corporation | 2 | $48 |
| Exelixis Inc. | 1 | $44 |
| AstraZeneca Pharmaceuticals LP | 2 | $43 |
Products named: DARZALEX, Epkinly, Lenvima, ZYNLONTA, IMBRUVICA, CABOMETYX, VENCLEXTA, CARVYKTI.
Industry payments across CO — which companies pay providers there.
